<DOC>
	<DOC>NCT00362479</DOC>
	<brief_summary>This is an open-label, single treatment study. All subjects will receive 6 months of oral contraceptive therapy with DR-1021. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.</brief_summary>
	<brief_title>Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive</brief_title>
	<detailed_description>The overall study duration for each patient will be approximately 8 months, which includes a screening period of approximately 4 weeks; a treatment period of approximately six months (six,28-day cycles); and a follow-up visit approximately 4 weeks after completion of study drug.</detailed_description>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal Not pregnant or breastfeeding Sexually active at risk of pregnancy Any contraindication to the use of oral contraceptives Pregnancy within the last 3 months Smoking &gt; 10 cigarettes per day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>pregnancy prevention</keyword>
	<keyword>oral contraceptives</keyword>
</DOC>